SCHEMBL4869591

SCHEMBL4869591

Fc1ccc(-c2coc3ncnc(NCc4ccccn4)c23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 3/20 0.52
TNF P01375 2/20 0.51
NOD1 Q9Y239 2/20 0.51
MAPK1 P28482 1/20 0.51
AURKA O14965 2/20 0.44
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DYRK1A Q13627 1/20 0.43
TP53 P04637 1/20 0.43
ABL1 P00519 1/20 0.43
SRC P12931 1/20 0.43
KMT2A Q03164 1/20 0.42
JAK2 O60674 1/20 0.42
LCK P06239 1/20 0.42
LYN P07948 1/20 0.42
CDK2 P24941 1/20 0.42
TYK2 P29597 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4869478 0.91 TNF (0.61) KCNA5TNFNOD1MAPK1AURKA
SCHEMBL4867940 0.79 KCNA5 (0.47) KCNA5SRCJAK2LCKLYN
SCHEMBL3387956 0.78 TNF (0.83) KCNA5TNFNOD1MAPK1ALDH1A1
SCHEMBL15452584 0.72 TP53 (0.54) TNFNOD1MAPK1ALDH1A1POLB
SCHEMBL4867404 0.70 KCNH2 (0.47) KCNA5TNFNOD1MAPK1SRC
SCHEMBL4865901 0.70 KCNH2 (0.49) KCNA5TNFNOD1MAPK1SRC
SCHEMBL4863471 0.70 CDK2 (0.50) KCNA5TNFNOD1MAPK1SRC
SCHEMBL4860362 0.70 KCNH2 (0.51) KCNA5TNFNOD1MAPK1SRC
SCHEMBL27875856 0.69 KCNA5 (0.69) KCNA5TNFNOD1MAPK1SRC
SCHEMBL4864910 0.69 PIK3CA (0.52) KCNA5ALDH1A1SRCJAK2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 KCNA5 6/4885TNF 4552/4885NOD1 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.